Clinical trials: Diffuse Parenchymal Lung Diseases
Idiopathic Pulmonary Fibrosis
Inspiratory Effort and Respiratory Mechanics in Spontaneously Breathing Patients With Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Matched Control Study
Idiopathic pulmonary fibrosis is a life-threatening lung disease characterized by progressive deterioration of lung function and a median survival time of 3-5 years from diagnosis.
- Trial name
- IERATIC (NCT05313672)
- Volunteers
- 20 people
- Sponsor
- Roberto Tonelli
Lung Diseases, Interstitial, Fibrosis Lung
Research of Burden of Interstititial Lung Diseases in Turkey
The aim of our study is to investigate the etiological distribution of ILD, epidemiological characteristics of ILD cases such as age, gender, geography, smoking, occupation, economic status, education, and comorbidities.
- Trial name
- RBILD (NCT03995654)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Karadeniz Technical University
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Pulmonary Arterial Hypertension, Interstitial Lung Disease
A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
The purpose of this research study is to find out more about the drug treprostinil via inhaler and the mechanisms of why patients with pulmonary arterial hypertension related to Interstitial Lung disease (PAH-ILD) have…
- Conditions
- Pulmonary Arterial Hypertension, Interstitial Lung Disease, Healthy Adults
- Trial name
- NCT05564637
- Testing
- Treprostinil, Right Heart Catheterization (RHC) while exercising, Optional Muscle Biopsy
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Interstitial Lung Disease, Lung Cancer
Assessment of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) as Measured Using a New Device (Inflammacheck™) in Patients With Interstitial Lung Disease, Lung Cancer and Healthy Volunteers.
A cross-sectional study of EBC H2O2 levels, as measured by a novel device, 'Inflammacheck™', and other markers of disease severity in patients with ILD and Lung Cancer.
- Trial name
- EXHALE 1B (NCT04061356)
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Interstitial Lung Disease, Idiopathic Interstitial Pneumonias
FAPI PET for Lung Fibrosis
This is a prospective exploratory biodistribution study in patients with interstitial lung disease (ILD). The purpose of this research study is to determine where and to which degree the FAPI tracer (68Ga-FAPI-46) accumulates in…
- Conditions
- Interstitial Lung Disease, Idiopathic Interstitial Pneumonias, Drug-Induced Pneumonitis, Hypersensitivity Pneumonitis
- Trial name
- FAPI ILD (NCT05365802)
- Testing
- 68Ga-FAPi-46, Computed Tomography, Positron Emission Tomography
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Los Angeles
Asbestos Exposure
Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population
This is a single-arm phase II trial to assess the biological activity (in a sub-cohort using a Simon two-stage Phase II design) and toxicity of Artichoke Whole Phytocomplex Concentrate (WPC).
- Trial name
- ABOCA1 (NCT02076672)
- Testing
- Artichoke WPC
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Acute Exacerbation, Idiopathic Pulmonary Fibrosis
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
Idiopathic pulmonary fibrosis (IPF) is a chronic disease, leading to poor lung function with a median survival of 2-3 years. Acute exacerbation of idiopathic IPF is a complication associated with a mortality rate > 50%.
- Conditions
- Acute Exacerbation, Idiopathic Pulmonary Fibrosis, Home Spirometry
- Trial name
- NCT03979430
- Testing
- Home spirometry
- Where
- 4 sites in Germany
- Volunteers
- 47 people
- Sponsor
- Heidelberg University
Systemic Sclerosis, Diffuse Sclerosis Systemic
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment…
- Conditions
- Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
- Trial name
- SSc (NCT03630211)
- Testing
- Cyclophosphamide, Mesna, Rituximab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Paul Szabolcs
Combined Pulmonary Fibrosis and Emphysema Syndrome, Pulmonary Fibrosis
Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome
The combined pulmonary fibrosis and emphysema syndrome (CPFE) individualized by our group in 2005 is characterized by an often severe dyspnea, almost exclusive male predominance, and often major, profound impairment of gas…
- Conditions
- Combined Pulmonary Fibrosis and Emphysema Syndrome, Pulmonary Fibrosis, Emphysema, Healthy Subjects
- Trial name
- GENES-SEF (NCT02439528)
- Testing
- Genetic analysis
- Where
- 3 sites in France
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML)
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
The purpose of this study is to learn more about the effects of (classification determinant) CD34+ stem cell selection on graft versus host disease (GVHD) in children, adolescents, and young adults.
- Conditions
- Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML)
- Trial name
- NCT02061800
- Testing
- CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Diane George
Interstitial Lung Diseases, Systemic Sclerosis Associated Interstitial Lung Disease
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
This post-approval registry study is planned to generate data to address remaining questions on long-term effectiveness and to better characterize longer term beneficial effects of Nintedanib in patients with systemic sclerosis…
- Trial name
- NCT07080125
- Testing
- Ofev®
- Where
- Switzerland
- Volunteers
- 2,000 people
- Sponsor
- Boehringer Ingelheim
Sarcoidosis, Pulmonary, Sarcoidosis Skin
the PHENOSAR Trial: Use of Antibiotics in Treatment of Sarcoidosis
In this study it is investigated whether treatment with azithromycin in combination with doxycycline reduces the bacterial load of C.
- Trial name
- NCT05291468
- Testing
- FDG-PET/CT
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- St. Antonius Hospital
Pulmonary Fibrosis
Pulmonary Fibrosis and Telomerase Mutation Study
This study is an observational and retrospective study of patients with pulmonary fibrosis associated or not with telomerase mutation.
- Trial name
- NCT01501578
- Where
- France
- Volunteers
- 81 people
- Sponsor
- Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires
Idiopathic Pulmonary Fibrosis
Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This study is designed to investigate whether GC1008, an antibody that neutralizes TGFb, is safe in treating patients with idiopathic pulmonary fibrosis. The highest dose without excessive side effects will be identified.
- Trial name
- NCT00125385
- Testing
- GC1008
- Where
- 8 sites in United States, Belgium
- Volunteers
- 25 people
- Sponsor
- Genzyme, a Sanofi Company
Idiopathic Pulmonary Fibrosis
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
This is a randomized, multi-center, open-label Phase II clinical trial to determine the efficacy of combined plasma exchange (PEX), rituximab, and conventional corticosteroid administration, in comparison to corticosteroids…
- Trial name
- NCT01524068
- Testing
- Standard Steroid Treatment, The Standard Steroid Treatment, Plasma Exchange and rituximab
- Where
- 5 sites in United States
- Sponsor
- University of Pittsburgh
Idiopathic Pulmonary Fibrosis, Fibrosis
A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis
This is a Phase 2, multicenter, multinational, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, pharmacokinetics (PK), quality of life and exploratory pharmacodynamics (PD) of two treatment…
- Conditions
- Idiopathic Pulmonary Fibrosis, Fibrosis, Idiopathic Interstitial Pneumonias, Pathologic Processes
- Trial name
- NCT03142191
- Testing
- CC-90001
- Where
- 112 sites in United States, Australia and 11 more
- Volunteers
- 138 people
- Sponsor
- Celgene
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Validation of AI-Based Detection of Idiopathic Pulmonary Fibrosis in Serial Chest Radiographs: A Retrospective Longitudinal Study
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic lung disease of unknown cause with a median survival of only 3-5 years after diagnosis.
- Trial name
- NCT07712952
- Testing
- VUNO Med-Chest X-ray
- Where
- South Korea
- Volunteers
- 175 people
- Sponsor
- Chung-Ang University Hospital
Idiopathic Pulmonary Fibrosis
Microaspiration in Pulmonary Fibrosis
Hypothesis 1: Microaspiration, as diagnosed by bronchoalveolar lavage (BAL) pepsin, is common in patients with IPF. Hypothesis 2a: Baseline clinical variables and co-morbid conditions are risk factors for microaspiration in…
- Trial name
- ROMI (NCT01150591)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Idiopathic Pulmonary Fibrosis
Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
This is a Phase 2a, single -center, randomized, double-blind, placebo-controlled study to evaluate type 1 collagen deposition in the lungs following once-daily treatment with PLN-74809 for 12-weeks.
- Trial name
- PLN-74809 (NCT05621252)
- Testing
- PLN-74809
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pliant Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.